These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 2628292)

  • 1. Hepatic function in relation to acetylator phenotype in children treated with antitubercular drugs.
    Seth V; Beotra A
    Indian J Med Res; 1989 Sep; 89():306-9. PubMed ID: 2628292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children.
    Martinez-Roíg A; Camí J; Llorens-Terol J; de la Torre R; Perich F
    Pediatrics; 1986 Jun; 77(6):912-5. PubMed ID: 3487069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.
    Ylitalo P; Auterinen L; Marttinen A; Koivula T
    Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl)].
    Musch E; Eichelbaum M; Wang JK; von Sassen W; Castro-Parra M; Dengler HJ
    Klin Wochenschr; 1982 May; 60(10):513-9. PubMed ID: 7098379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti tubercular treatment induced hepatotoxicity: does acetylator status matter?
    Singh J; Garg PK; Thakur VS; Tandon RK
    Indian J Physiol Pharmacol; 1995 Jan; 39(1):43-6. PubMed ID: 7705868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis.
    O'Brien RJ; Long MW; Cross FS; Lyle MA; Snider DE
    Pediatrics; 1983 Oct; 72(4):491-9. PubMed ID: 6604257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hepatotoxicity of the combination of isoniazid-rifampicin in African children. Role of malnutrition and HB virus].
    Gendrel D; Nardou M; Mouba JF; Gahouma D; Moussavou A; Boguikouma JB
    Arch Fr Pediatr; 1989 Nov; 46(9):645-8. PubMed ID: 2604523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of isoniazid in hepatotoxicity with the INH-rifampicin combination in tuberculosis in children].
    Dieu MJ
    J Med Lyon; 1972 Oct; 53(234):1323-4 passim. PubMed ID: 4539047
    [No Abstract]   [Full Text] [Related]  

  • 9. Low rates of hepatotoxicity in HIV-infected children on anti-retroviral therapy with and without isoniazid prophylaxis.
    Gray D; Nuttall J; Lombard C; Davies MA; Workman L; Apolles P; Eley B; Cotton M; Zar HJ
    J Trop Pediatr; 2010 Jun; 56(3):159-65. PubMed ID: 19710246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
    Ellard GA
    Rev Mal Respir; 1984; 1(4):207-19. PubMed ID: 6505358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients.
    Sotsuka T; Sasaki Y; Hirai S; Yamagishi F; Ueno K
    In Vivo; 2011; 25(5):803-12. PubMed ID: 21753138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between serum and urinary sulphadimidine acetylation as predictors of isoniazid acetylator status in patients with pulmonary tuberculosis.
    Singh SP; Pande JN; Khilnani GC; Kailash S
    Indian J Chest Dis Allied Sci; 1996; 38(1):5-11. PubMed ID: 16892742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Course of serum alkaline phosphatase during treatment with isoniazid and rifampicin].
    Toppet M; Vainsel M; Cantraine F; Franckson M
    Arch Fr Pediatr; 1985 Feb; 42(2):79-80. PubMed ID: 4004474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rifampicin and isoniazid on liver function.
    Lal S; Singhal SN; Burley DM; Crossley G
    Br Med J; 1972 Jan; 1(5793):148-50. PubMed ID: 5007842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatic tolerance in man of rifampicin-isoniazid association].
    Toulet J; Plomteux G; Viteau JM; Abiven M; Bonfante N
    J Med Liban; 1971; 24(6):651-8. PubMed ID: 5146848
    [No Abstract]   [Full Text] [Related]  

  • 16. An unusual recurrence of antitubercular drug induced hepatotoxicity in a child.
    Bhatia S; Tullu MS; Kannan S; Gogtay NJ; Thatte UM; Lahiri KR
    J Postgrad Med; 2011; 57(2):147-52. PubMed ID: 21654145
    [No Abstract]   [Full Text] [Related]  

  • 17. [Significance of the acetylator phenotype and initial oral/intravenous rifampicin administration in the treatment of tuberculosis].
    Loos U; Musch E; Schwabe HK
    Pneumologie; 1990 Feb; 44 Suppl 1():488-9. PubMed ID: 2367445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatotoxicity of rifampicin and isoniazid in children.
    Casteels-Van Daele M; Igodt-Ameye L; Corbeel L; Eeckels R
    J Pediatr; 1975 May; 86(5):739-41. PubMed ID: 1079531
    [No Abstract]   [Full Text] [Related]  

  • 19. Population screening for isoniazid acetylator phenotype.
    Seifart HI; Parkin DP; Botha FJ; Donald PR; Van Der Walt BJ
    Pharmacoepidemiol Drug Saf; 2001; 10(2):127-34. PubMed ID: 11499851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis.
    Gurumurthy P; Krishnamurthy MS; Nazareth O; Parthasarathy R; Sarma GR; Somasundaram PR; Tripathy SP; Ellard GA
    Am Rev Respir Dis; 1984 Jan; 129(1):58-61. PubMed ID: 6367570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.